LOFEXIDINE HYDROCHLORIDE (lofexidine) by Novitium Pharma is alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. First approved in 2025.
Drug data last refreshed 15h ago
alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution
Lofexidine for Adults Undergoing Lumbar Spine Surgery
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
Worked on LOFEXIDINE HYDROCHLORIDE at Novitium Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.